List of Radiopharmaceuticals/Radiotherapies Companies with Phase 3 Active Clinical Trial - 15

Actinium Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or adoptive cell therapies.

Nasal breathing is a very important function of human life and any obstruction in the nasal airway also known as a congested or blocked nose, can dramatically impact the quality of life.The VIVAER treatment, performed in a doctor’s office, is a non-invasive procedure without any incisions. The patient'snasal valve area is gently reshaped using low-temperature radiofrequency energy with lasting results.

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating zelenectide pevedotin, previously BT8009, a Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC molecule targeting EphA2, a historically undruggable target; and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137, in company-sponsored clinical trials. Additionally, the company is developing Bicycle® Radio Conjugates (BRC™) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases beyond oncology. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Cambridge, MA.

At Chimerix, we are on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. With a focus in oncology, we are devoted to filling gaps in the treatment paradigm.

Clarity Pharmaceuticals is a clinical stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products. It was founded in 2010 and is based in Australia. The company focuses on addressing the growing need for the use of radiopharmaceutical therapies in the treatment of serious diseases.

At Creo Medical we are dedicated to improving patient outcomes by bringing advanced energy to therapeutic endoscopy. Our integrated electrosurgery unit delivers Bipolar Radiofrequency for precise dissection and resection and Microwave energy for controlled ablation and coagulation. This technology sets a new standard for Endoscopic Submucosal Dissection with our new Speedboat RS2 instrument: the Bipolar Radiofrequency cut allows precise dissection and the microwave coagulation provides controlled haemostasis while the protective hull reduces the risk of muscle damage and the integrated injection needle helps to maintain submucosal lift without instrument changes.

Cynosure is a leader in the medical devices industry specializing in aesthetic medicine and cosmetic procedures.

On June 6, 2024, AstraZeneca announced the successful completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates (RCs). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most advanced programme, FPI-2265, a potential new treatment for patients with metastatic castration-resistant prostate cancer (mCRPC), and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based RCs to AstraZeneca. It also strengthens AstraZeneca’s presence in and commitment to Canada. As a result of the acquisition, Fusion has become a wholly owned subsidiary of AstraZeneca, with operations in Canada and the US. At Fusion, we are pushing the boundaries of science to create innovative precision medicines for cancer. We are a clinical-stage biopharmaceutical company developing next-generation radiopharmaceuticals as precision medicines for the treatment of cancer. We have developed our Targeted Alpha Therapies, or TAT, platform together with our proprietary Fast-Clear™ linker technology to enable us to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the therapies to tumors.

ImaginAb is a clinical stage, revenue-generating global biotechnology company developing the next generation of imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The lead candidate 89Zr crefmirlimab berdoxam (CD8 ImmunoPET™) imaging agent is currently in Phase II clinical trials and has been licensed by numerous pharmaceutical and biotech companies for use in imaging within their immunotherapy clinical trials, primarily in oncology.

PASSION FOR PRECISION. ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment. Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of a novel, first-in-class medical radioisotopes and generator platform for a new generation of targeted cancer diagnostics and therapies. Furthermore, ITM is developing a proprietary portfolio and growing pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors like lung, ovarian or breast cancer. ITM’s main objectives, together with its scientific, medical and industrial collaboration partners worldwide, are to significantly improve treatment outcomes and quality of life for cancer patients while at the same time reducing side effects and improving health economics through a new generation of Targeted Radionuclide Therapies in Precision Oncology. For more information please visit: www.itm-radiopharma.com. Please see our Community Guidelines: https://isotope-technologies-munich.com/service/community-guidelines

POINT Biopharma develops next-generation radioligand therapies for the treatment of cancer. On Dec. 27, 2023, Lilly Completes Acquisition of POINT Biopharma.

Leader in targeted radiopharmaceuticals to improving cancer patient survival. Broad pipeline of innovative drugs against solid tumor targets

The company uses biology-guided radiotherapy to detect and respond to signals emitted from cancer cells, and use them to guide treatment.

SalutarisMD is a medical device company that specializes in engineering a novel ophthalmic treatment for Wet age-related Macular Degeneration with a minimally invasive procedure.

Telix is a biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic ('theranostic') radiopharmaceuticals. Telix is headquartered in Melbourne, Australia with commercial operations in the United States, Europe (Belgium and Switzerland) and Japan. Telix is developing a portfolio of radiopharmaceutical products that aims to address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX).